Second-line therapy for small-cell lung cancer. - Wikidata - wikimedia - TriplyDB

Second-line therapy for small-cell lung cancer.

Second-line therapy for small-cell lung cancer.

http://www.wikidata.org/entity/Q37866795

about

Radiation/paclitaxel treatment of p53-abnormal non-small cell lung cancer xenograft tumor and associated mechanism.MicroRNA-299-3p promotes the sensibility of lung cancer to doxorubicin through directly targeting ABCE1.Efficacy of different monotherapies in second-line treatment for small cell lung cancer: a meta-analysis of randomized controlled trials.Cisplatin for small cell lung cancer: Associated publications in Science Citation Index Expanded.HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.Second-line therapy for small cell lung cancer: exploring the potential role of circulating tumor cells Synergism of cyclin-dependent kinase inhibitors with camptothecin derivatives in small cell lung cancer cell lines.miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence.MCAM Mediates Chemoresistance in Small-Cell Lung Cancer via the PI3K/AKT/SOX2 Signaling Pathway.

P2860

Q35964863-28E80FCF-1E9B-46A3-943C-9A38F8735A93 Q36261264-80DC90EB-2B39-4B8D-9A46-8C52B4D49258 Q36412432-B6F91A67-D4DC-431F-8DCD-7B2827CBB11A Q36611813-5D292120-9503-4DEA-92A3-999A39C32A78 Q37728631-200925E9-9B3D-497D-9619-1E2CC33DD187 Q38549648-90D02DF2-155E-4BD3-A2DE-FB72CE4ADCFE Q39022901-E52BA4AE-6CA5-4415-8BD0-6B290541E067 Q39289196-561DB2CC-F437-422B-A250-545FB785CF1A Q50926633-61D740C5-342A-407C-B60D-71AE52F8CD13

P2860

Second-line therapy for small-cell lung cancer.

http://www.wikidata.org/entity/Q37866795

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Second-line therapy for small-cell lung cancer.

@en

Second-line therapy for small-cell lung cancer.

@nl

type

label

Second-line therapy for small-cell lung cancer.

@en

Second-line therapy for small-cell lung cancer.

@nl

prefLabel

Second-line therapy for small-cell lung cancer.

@en

Second-line therapy for small-cell lung cancer.

@nl

P1433

Q37866795-9DE628CB-C1FE-4E88-82B1-C7E2846BF9DC

P1476

Q37866795-BDC33ECD-DD49-4965-A7C6-495D55926DEC

P2093

Q37866795-B8306369-B35A-4EED-9149-6840F868663D

P2860

Q37866795-184E1969-C56F-4FCD-9DB6-29A9B2DA6218

Q37866795-4F874412-AAE9-480E-BF59-64471EFE0F1E

Q37866795-66A8537D-19B2-4BEE-BC40-02BBAFF9C23D

Q37866795-84844081-CDFE-4A8E-ACC5-97793B700D12

Q37866795-898A5E8E-6F30-4742-B9F4-77AFD6C54BA7

Q37866795-9167738F-9FF4-4243-9799-3168F6D5B906

Q37866795-9B4D8F5B-95E4-4349-ACC8-FE0DD45E0575

Q37866795-AA287BDB-70F3-48D1-AC3A-AF37AD660D8F

Q37866795-AA51F550-2B3E-486A-A810-CC732CF4A109

Q37866795-B0EA1802-A30A-44BE-A777-1418CE75F4F3

P304

Q37866795-940E9211-36DD-4E35-B9BB-2EB11AD62729

P31

Q37866795-B9210CF9-E5F5-4F10-8F9F-D235724CF172

P356

Q37866795-ADA4D731-09EA-4D14-8FB3-B80962393183

P433

Q37866795-737E255F-B2BD-4961-8944-468282DB0730

P478

Q37866795-1D98E040-9F0B-48AF-8CC2-2A8554FFC67F

P577

Q37866795-163A3F47-1175-442E-86AD-BC63615615CA

P698

Q37866795-53FB78B0-09E4-4E96-8E48-97C50EB43C85

P921

Q37866795-4729048B-FEB9-4443-ACB9-330FA9881ED6

P356

P1433

Expert Review of Anticancer Therapy

P1476

Second-line therapy for small-cell lung cancer.

@en

P2093

Alexander Schmittel

http://www.w3.org/2001/XMLSchema#string

P2860

Combination of cisplatin, ifosfamide, and irinotecan with rhG-CSF support for the treatment of refractory or relapsed small-cell lung cancer.

Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.

Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer.

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer.

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients.

Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer.

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

P304

631-637

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.11.7

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21504329

http://www.w3.org/2001/XMLSchema#string

P921